Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease

Journal of the American Society of Nephrology

Volumn 14, Issue 10, 2003, Pages 2611-2617

  Zoccali, Carmine ^a,c   Mallamaci, Francesca ^a   Tripepi, Giovanni ^a   Benedetto, Francesco A ^b   Parlongo, Saverio ^a   Cutrupi, Sebastiano ^a   Iellamo, Domenico ^a   Bonanno, Graziella ^d   Rapisarda, Francesco ^d   Fatuzzo, Pasquale ^d   Seminara, Giuseppe ^d   Cataliotti, Alessandro ^d   Malatino, Lorenzo Salvatore ^d  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b Morelli Hospital   (Italy)

^c BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE Y;

ADRENALIN RELEASE; ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHRONIC DISEASE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; DIAGNOSTIC VALUE; DIALYSIS; DISEASE DURATION; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NORADRENALIN BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RISK FACTOR;

EID: 0141678239     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000089026.28617.33     Document Type: Article

References (43)

1. Morris MJ, Cox HS, Lambert GW, Kaye DM, Jennings GL, Meredith IT, Esler MD: Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension 29: 137-143, 1997
2. Pedrazzini T, Brunner HR, Waeber B: Neuropeptide Y and cardiovascular regulation. Curr Opin Nephrol Hypertens 2: 106-113, 1993
3. Koenig JI: Regulation of the hypothalamo-pituitary axis by neuropeptide Y. Ann N Y Acad Sci 611: 317-328, 1990
4. Persson H, Andreasson K, Kahan T, Eriksson SV, Tidgren B, Hjemdahl P, Hall C, Erhardt L: Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail 4: 73-82, 2002
5. Ullman B, Hulting J, Lundberg JM: Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 15: 454-461, 1994
6. Klin M, Waluga M, Rudka R, Madej A, Janiszewska M, Grzebieniak E, Wesolowky A: Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip. Boll Chim Farm 137: 306-313, 1998
7. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 30: 23-27, 1997
8. Mouri T, Sone M, Takahashi K, Itoi K, Totsune K, Hayashi Y, Hasegawa S, Ohneda M, Murakami O, Miura Y: Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma. Clin Sci (Lond) 83: 205-211, 1992
9. Hegbrant J, Martensson L, Thysell H, Ekman R, Boberg U: Changes in plasma levels of vasoactive substances during routine acetate and bicarbonate hemodialysis. Clin Nephrol 41: 106-112, 1994
10. Crum R, Fairchild R, Bronsther O, Dominic W, Ward D, Fernandez R, Brown MR: Neuroendocrinology of chronic renal failure and renal transplantation. Transplantation 52: 818-823, 1991
11. Odar-Cederlof I, Ericsson F, Theodorsson E, Kjellstrand CM: Is neuropeptide Y a contributor to volume-induced hypertension? Am J Kidney Dis 31: 803-808, 1998
12. Hegbrant J, Thysell H, Ekman R: Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment. Scand J Urol Nephrol 26: 169-176, 1992
13. Takahashi K, Mouri T, Itoi K, Sone M, Ohneda M, Murakami O, Nozuki M, Tachibana Y, Yoshinaga K: Increased plasma immunoreactive neuropeptide Y concentrations in phaeochromocytoma and chronic renal failure. J Hypertens 5: 749-753, 1987
14. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998
15. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS: Neuropeptide Y and alterations in left ventricular mass and function in patients in patients with end stage renal disease. J Hypertension, in press
16. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61: 609-614, 2002
17. Zukowska-Grojec Z, Vaz AC: Role of neuropeptide Y (NPY) in cardiovascular responses to stress. Synapse 2: 293-298, 1988
18. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, Ziegler M, Allen RS, Brown MR: Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 86: 43-48, 1989
19. Ullman B, Franco-Cereceda A, Hulting J, Lundberg JM, Sollevi A: Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med 228: 583-589, 1990
20. Millar BC, Schluter KD, Zhou XJ, McDermott BJ, Piper HM: Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. Am J Physiol 266(5 Pt 1):C1271-C1277, 1994
21. Bohm M, Grabel C, Knorr A, Erdmann E: Treatment in hypertensive cardiac hypertrophy I. Neuropeptide Y and beta-adrenoceptors. Hypertension 25: 954-961, 1995
22. Sung CP, Arleth AJ, Feuerstein GZ: Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes. Circ Res 68: 314-318, 1991
23. Pernow J, Lundberg JM, Kaijser L: Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci 40: 47-54, 1987
24. Medeiros MS, Turner AJ: Metabolism and functions of neuropeptide Y. Neurochem Res 21: 1125-1132, 1996
25. Medeiros MD, Turner AJ: Processing and metabolism of peptide-YY: Pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 134: 2088-2094, 1994
26. Odar-Cederlof I, Ericsson F, Theodorsson E, Kjellstrand CM: Is neuropeptide Y a contributor to volume-induced hypertension? Am J Kidney Dis 31: 803-808, 1998
27. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 30: 23-27, 1997
28. Mouri T, Sone M, Takahashi K, Itoi K, Totsune K, Hayashi Y, Hasegawa S, Ohneda M, Murakami O, Miura Y: Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma. Clin Sci (Lond) 83: 205-211, 1992
29. Hegbrant J, Thysell H, Ekman R: Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment. Scand J Urol Nephrol 26: 169-176, 1992
30. Hegbrant J, Martensson L, Thysell H, Ekman R, Boberg U: Changes in plasma levels of vasoactive substances during routine acetate and bicarbonate hemodialysis. Clin Nephrol 41: 106-112, 1994
31. Briggs JD, Berthoux FJE: Predictions of future growth of ESRD prevalence. Kidney Int 57: S46-S48, 2000
32. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 13: 1918-1927, 2002
33. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999
34. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476, 2000
35. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138-141, 1998
36. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
37. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
38. Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34(4 Pt 2): 724-728, 1999
39. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40: 41-46, 2002
40. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cataliotti A: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105: 1354-1359, 2002
41. Forsgren S: Neuropeptide Y-like immunoreactivity in relation to the distribution of sympathetic nerve fibers in the heart conduction system. J Mol Cell Cardiol 21: 279-290, 1989
42. Balasubramaniam AA: Neuropeptide Y family of hormones: Receptor subtypes and antagonists. Peptides 18: 445-457, 1997
43. Akagi S, Nagake Y, Sugimoto T, Nakao K, Yamasaki H, Ichikawa H, Makino H: Plasma neuropeptide Y concentrations in patients on hemodialysis. Nephron 92: 333-338, 2002